Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

UMBRALISIB vs UPADACITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

UMBRALISIB vs UPADACITINIB: Safety Overview

Metric UMBRALISIB UPADACITINIB
Total FAERS Reports 293 65,656
Deaths Reported 30 2,406
Death Rate 10.2% 3.7%
Hospitalizations 97 15,931
Average Patient Age 69.0 yrs 57.4 yrs
% Female Patients 43.8% 71.2%
FDA Approval Date Feb 5, 2021 Apr 26, 2024
Manufacturer N/A AbbVie Inc.
Route N/A ORAL
Marketing Status Discontinued Prescription